Abstract

Osteoporosis (OP) is a generalized skeletal disorder characterized by low bone mineral density (BMD), deterioration of the microarchitecture of bone tissue and susceptibility to fracture. Most frequently it occurs in postmenopausal women and the aged. It is a chronic condition of multifactorial etiology and is a major global healthcare problem in developed and rising in developing countries. Patients with uncomplicated OP are usually asymptomatic which contributes to serious under-diagnosing of this potentially devastating condition. It is estimated that less than half of patients with OP are diagnosed in many developed countries. Therefore preventive measures and timely diagnosis have to be a key aspect of management of this disorder. In this article we briefly underline pato-physiology of the disorder, review current methods of measuring bone mineral density, describe risk factors and evaluate current and potential therapies.

Highlights

  • IntroductionINDIRA KULENOVIĆ ET AL.: OSTEOPOROSIS – CURRENT TRENDS IN DIAGNOSIS AND MANAGEMENT three-fold , from . million in to . million by ( )

  • BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES 2006; 6 (1): 24-28INDIRA KULENOVIĆ ET AL.: OSTEOPOROSIS – CURRENT TRENDS IN DIAGNOSIS AND MANAGEMENT three-fold, from . million in to . million by ( )

  • In The World Health Organization (WHO) proposed a clinical definition of osteoporosis based on measurement of bone mineral density (BMD)

Read more

Summary

Introduction

INDIRA KULENOVIĆ ET AL.: OSTEOPOROSIS – CURRENT TRENDS IN DIAGNOSIS AND MANAGEMENT three-fold , from . million in to . million by ( ). With low estrogen bone resorption increases and the actual mechanism is a decrease in the inhibition of osteoclast formation, resulting in bone loss In women this occurs at the time of menopause. DEXA is the most precise and recommended method for BMD measurement It is a senstitive technique and can detect small changes in bone mass by comparing the patients bone density to that of healthy (T score) and to age–matched adults (Z score). There are no definitive guidelines on the use of bone markers because of the tremendous variability in the values in a single patient and among patients in a single group ( ) They may be useful in some patients for monitoring early response to therapy as marker will show the effect of treatment much faster ( - months) than bone density measurements which usually require - years of an intervention to register a significant change ( , ). Smoking is another risk factor, so measures to quit smoking could be necessary

PHARMACOTHERAPY
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call